Shanghai Opm Biosciences Co., Ltd. (688293)
SSE SSE Primary Summary
688293 Chart
People also search for
Shanghai Opm Biosciences Co., Ltd. (688293) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Shanghai Opm Biosciences Co., Ltd. ever had a stock split?
Shanghai Opm Biosciences Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Zhihua Xiao CEO | SSE Exchange | CNE100005PF1 ISIN |
| CN Country | 285 Employees | 15 Sep 2025 Last Dividend | 12 May 2023 Last Split | - IPO Date |
Overview
Shanghai OPM Biosciences Co., Ltd., established in 2013 and based in Shanghai, China, operates both domestically and internationally. The company is specialized in the provision of cell culture media and Contract Development and Manufacturing Organization (CDMO) services. With its expertise in biologics, Shanghai OPM Biosciences offers comprehensive solutions tailored to meet the needs of the biotechnology and pharmaceutical industries.
Products and Services
- OPM Cell Culture Media Services
Offers a variety of cell culture media solutions including OPM-CHO platform for CHO cell lines, OPM-293 platform for HEK293 cells, OPM-VAC platform for vaccine production, OPM-Hybri platform for hybridoma cells, and classical media for general purposes. These platforms are designed to enhance cell growth and productivity, supporting a wide range of bioprocessing needs.
- Customized Media Solutions
Provides tailored media solutions to meet specific client requirements, optimizing the cell culture process for improved yield and quality of the final bioproduct.
- OEM Media Manufacturing Services
Offers original equipment manufacturer (OEM) services for media production, enabling organizations to have their proprietary media formulations manufactured to the highest standards.
- Biologics CDMO Services
- Antibody Discovery: Provides comprehensive services for the discovery of new antibodies, leveraging advanced techniques and platforms.
- Stable Cell Line Development & Cell Banking Platform: Offers services for stable cell line development and the creation of master and working cell banks for future manufacturing needs.
- Upstream Process Development: Focuses on the optimization of cell culture conditions to maximize production yields.
- Downstream Process Development: Involves the purification and refinement of biologics to ensure product purity and quality.
- OPM Formulation Development Platform: Provides formulation development services to ensure stability and efficacy of the final biologic product.
- Quality Control and Product Characterization of Biologics: Conducts thorough quality control and characterization studies to confirm the biologic product meets all required standards.
- Pilot Scale Production Services: Supports the transition from laboratory scale to commercial scale production, ensuring process scalability and efficiency.
